Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12412447 | PMC |
| http://dx.doi.org/10.5334/gh.1465 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predicting acute postsurgical pain in the postanesthesia care unit: risk tool development and internal validation.
Pain Rep
October 2025
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Introduction: Moderate-to-severe acute postsurgical pain (APSP) is experienced by approximately 30% of surgical patients.
Objectives: To improve early APSP management, we developed 2 pragmatic and generalizable point-of-care risk tools to preoperatively predict moderate-to-severe and severe APSP in the postanaesthesia care unit (PACU).
Methods: This was a multicenter prospective cohort study of adult patients undergoing elective surgical procedures between May 2021 and May 2023.
Optimism Model by a Cardiology Pharmacist in Breaking Bad News Among Patients with CTRCD and its Impact on Outcomes.
Glob Heart
September 2025
Cardio-Oncology Clinic, Baghdad Medical City, Baghdad, Iraq.
Super-Refractory Status Epilepticus Diagnosis, Management, and Prognostication: An International Survey Study.
Neurol Clin Pract
October 2025
Department of Neurology, Division of Neurocritical Care and Emergency Neurology, Program in Trauma, University of Maryland, Baltimore, MD.
Background And Objectives: Guidelines for super-refractory status epilepticus (SRSE) evaluation, management, and prognostication are lacking. Characterization of practice patterns could identify trends and potential areas for future inquiry. We surveyed clinicians who manage SRSE to better understand practice approaches to SRSE evaluation, management, and prognostication.
View Article and Find Full Text PDFDevelopment and validation of a prognostic model for predicting the risk of allopurinol-induced severe cutaneous adverse reactions: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data.
Lancet Rheumatol
September 2025
Academic Rheumatology, University of Nottingham, Nottingham, UK.
Background: Allopurinol, the most prescribed urate-lowering drug, is a known cause of severe cutaneous adverse reactions. We aimed to develop and validate a model to assess the risk of allopurinol-induced severe cutaneous adverse reactions in adults newly prescribed allopurinol.
Methods: In this retrospective new-user cohort study, we developed and validated a prognostic model using primary care, hospitalisation, and mortality data extracted from the UK Clinical Practice Research Datalink (CPRD) primary care database, for the period Jan 1, 2001, to March 29, 2021.